Genetic and molecular changes in ovarian cancer

被引:79
作者
Hollis, Robert L. [1 ]
Gourley, Charlie [1 ]
机构
[1] Univ Edinburgh, Edinburgh Canc Res UK Ctr, MRC Inst Genet & Mol Med, Edinburgh EH4 2XR, Midlothian, Scotland
基金
英国医学研究理事会;
关键词
GRADE SEROUS CARCINOMA; CLEAR-CELL CARCINOMA; FALLOPIAN-TUBE; SOMATIC MUTATIONS; INTRAEPITHELIAL CARCINOMA; GERMLINE MUTATIONS; PROGNOSTIC-FACTOR; TUMOR-SUPPRESSOR; BRCA2; MUTATIONS; TP53;
D O I
10.20892/j.issn.2095-3941.2016.0024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Epithelial ovarian cancer represents the most lethal gynecological malignancy in the developed world, and can be divided into five main histological subtypes: high grade serous, endometrioid, clear cell, mucinous and low grade serous. These subtypes represent distinct disease entities, both clinically and at the molecular level. Molecular analysis has revealed significant genetic heterogeneity in ovarian cancer, particularly within the high grade serous subtype. As such, this subtype has been the focus of much research effort to date, revealing molecular subgroups at both the genomic and transcriptomic level that have clinical implications. However, stratification of ovarian cancer patients based on the underlying biology of their disease remains in its infancy. Here, we summarize the molecular changes that characterize the five main ovarian cancer subtypes, highlight potential opportunities for targeted therapeutic intervention and outline priorities for future research.
引用
收藏
页码:236 / 247
页数:12
相关论文
共 120 条
  • [31] Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas
    Etemadmoghadam, Dariush
    deFazio, Anna
    Beroukhim, Rameen
    Mermel, Craig
    George, Joshy
    Getz, Gad
    Tothill, Richard
    Okamoto, Aikou
    Raeder, Maria B.
    Harnett, Paul
    Lade, Stephen
    Akslen, Lars A.
    Tinker, Anna V.
    Locandro, Bianca
    Alsop, Kathryn
    Chiew, Yoke-Eng
    Traficante, Nadia
    Fereday, Sian
    Johnson, Daryl
    Fox, Stephen
    Sellers, William
    Urashima, Mitsuyoshi
    Salvesen, Helga B.
    Meyerson, Matthew
    Bowtell, David
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (04) : 1417 - 1427
  • [32] Ovarian Cancer Risk After Salpingectomy: A Nationwide Population-Based Study
    Falconer, Henrik
    Yin, Li
    Gronberg, Henrik
    Altman, Daniel
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (02):
  • [33] Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
    Farley, John
    Brady, William E.
    Vathipadiekal, Vinod
    Lankes, Heather A.
    Coleman, Robert
    Morgan, Mark A.
    Mannel, Robert
    Yamada, S. Diane
    Mutch, David
    Rodgers, William H.
    Birrer, Michael
    Gershenson, David M.
    [J]. LANCET ONCOLOGY, 2013, 14 (02) : 134 - 140
  • [34] Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma
    Gemignani, ML
    Schlaerth, AC
    Bogomolniy, F
    Barakat, RR
    Lin, O
    Soslow, R
    Venkatraman, E
    Boyd, J
    [J]. GYNECOLOGIC ONCOLOGY, 2003, 90 (02) : 378 - 381
  • [35] Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary
    Gershenson, David M.
    Sun, Charlotte C.
    Lu, Karen H.
    Coleman, Robert L.
    Sood, Anil K.
    Malpica, Anais
    Deavers, Michael T.
    Silva, Elvio G.
    Bodurka, Diane C.
    [J]. OBSTETRICS AND GYNECOLOGY, 2006, 108 (02) : 361 - 368
  • [36] Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma
    Gilks, C. Blake
    Ionescu, Diana N.
    Kalloger, Steve E.
    Koebel, Martin
    Irving, Julie
    Clarke, Blaise
    Santos, Jennifer
    Le, Nhu
    Moravan, Veronika
    Swenerton, Kenneth
    [J]. HUMAN PATHOLOGY, 2008, 39 (08) : 1239 - 1251
  • [37] Ovarian carcinoma pathology and genetics: recent advances
    Gilks, C. Blake
    Prat, Jaime
    [J]. HUMAN PATHOLOGY, 2009, 40 (09) : 1213 - 1223
  • [38] High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation
    Gorodnova, Tatiana V.
    Sokolenko, Anna P.
    Ivantsov, Alexandr O.
    Iyevleva, Aglaya G.
    Suspitsin, Evgeny N.
    Aleksakhina, Svetlana N.
    Yanus, Grigory A.
    Togo, Alexandr V.
    Maximov, Sergey Ya.
    Imyanitov, Evgeny N.
    [J]. CANCER LETTERS, 2015, 369 (02) : 363 - 367
  • [39] Increased Incidence of Visceral Metastases in Scottish Patients With BRCA1/2-Defective Ovarian Cancer: An Extension of the Ovarian BRCAness Phenotype
    Gourley, Charlie
    Michie, Caroline O.
    Roxburgh, Patricia
    Yap, Timothy A.
    Harden, Sharon
    Paul, Jim
    Ragupathy, Kalpana
    Todd, Radha
    Petty, Russell
    Reed, Nick
    Hayward, Richard L.
    Mitchell, Paul
    Rye, Tzyvia
    Schellens, Jan H. M.
    Lubinski, Jan
    Carmichael, James
    Kaye, Stan B.
    Mackean, Melanie
    Ferguson, Michelle
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15) : 2505 - 2511
  • [40] ARID1A, a Factor That Promotes Formation of SWI/SNF-Mediated Chromatin Remodeling, Is a Tumor Suppressor in Gynecologic Cancers
    Guan, Bin
    Wang, Tian-Li
    Shih, Ie-Ming
    [J]. CANCER RESEARCH, 2011, 71 (21) : 6718 - 6727